Rafarma Pharmaceuticals, Inc. (OTC:RAFA) is happy to announce commencement of tests for its new product “HempySleep”. The product was designed by the company to fight increasing problems of insomnia around the world. Insomnia-curing qualities of cannabis have been discussed for a long time by specialists around the world. Rafarma with its partnerships in Europe and Asia has had a goal to formulate the most effective solution that would restore its patients’ natural sleep cycles without negative side effects or developing dependency issues. Analgesic properties of HempySleep have been shown to achieve that goal plus, in some cases, demonstrated relief of chronic pain and multiple anxiety disorders. As Rafarma is currently also developing a special product for anxiety, HempySleep is planned to be used exclusively for sleep disorders.
The tests are expected to last until October 1st 2020, then the company intends to introduce the product in its pilot detox spa in Thailand. With the full introduction of HempySleep, the company hopes to increase its annual revenues by at least €5,000,000.
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
SOURCE: Rafarma Pharmaceuticals, Inc.